No abstract

Experienced drug takers and clinicians report that cocaine causes panic attacks. This claim is supported by laboratory evidence on the pharmacologic activity of the drug. In this paper, the authors have used an epidemiologic strategy to examine the suspected cocaine-panic association, with interview data from 5,896 adult household residents sampled in the early 1980s and followed prospectively for a collaborative multisite study of mental disorders in five US metropolitan areas: New Haven, Connecticut; Baltimore, Maryland; St. Louis, Missouri; Durham, North Carolina; and Los Angeles, California. The risk of panic attacks was observed to be greater for identified cocaine users in this sample, as compared with subjects who did not use cocaine during the follow-up interval. The cocaine-panic association remained strong after statistical adjustment for preexisting psychiatric conditions, use of alcohol and marijuana, and suspected sociodemographic risk factors for panic attacks. The risk was greatest among cocaine users who reported no marijuana use during the follow-up interval (estimated relative risk = 13.0, 95% confidence interval: 2.24-75.8). The study also identified other determinants for panic attack, including sex, marital status, employment status, job prestige, major depression, and heavy drinking.

No abstract

Introduction Nonarteritic anterior ischemic optic neuropathy (NAION), a rare visual disorder, has been reported in men using phosphodiesterase type 5 inhibitors (PDE5i) for erectile dysfunction. Aim We examined whether intermittent use of PDE5i is associated with acute NAION onset within approximately five half-lives following drug ingestion. Methods One hundred two ophthalmology centers in the United States and Europe identified potential cases of NAION. An expert adjudication committee conducted a blind review of the records of those with recent PDE5i use to classify cases as Definite, Possible, or not NAION. Subjects provided information on PDEi use via telephone interview. Each NAION case’s PDE5i exposure immediately prior to onset was compared against his recent patterns of use in an observational case–crossover design. A sample size of 40 cases with intermittent PDE5i exposure in the 30 days prior to NAION onset was needed to detect an odds ratio (OR) of 3.0 with 80% power. Main Outcome Measures The daily relative risk for acute NAION on days within five half-lives of PDE5i use vs. other days was estimated via an OR obtained from conditional logistic regression. Results Among 43 Definite NAION cases with PDE5i exposure in the prior 30 days, the OR was 2.15 (95% confidence interval [CI]: 1.06, 4.34). When 21 Possible NAION cases were included (n = 64), the OR was 2.36 (95% CI: 1.33, 4.19). Conclusions We found an approximately twofold increased risk of acute NAION within five half-lives of PDE5i use compared with use in a more prior time period. Bias from inaccurate recall of exposure was unlikely to have substantially affected the results. Based on our results, we estimate that weekly use of PDE5i adds three NAION cases per 100,000 men 50 years and older annually.

Objective The incidence rate of suicidal ideation amongst current and former smokers versus never smokers is not known. Main Findings The age-adjusted incidence of suicidal ideation was highest among current smokers, followed by former, and never smokers. The adjusted hazard for suicide ideation was 2.22 (95%CI=1.48, 3.33) and 1.19 (95%CI=0.78, 1.82) for current and former smokers respectively, compared to never smokers. Conclusion Current smokers have increased risks of suicidal ideation above and beyond the risk for never and former smokers regardless of age, gender, history of depressive disorder and/or anxiety symptoms, and alcohol abuse/dependence. Smoking cessation might be beneficial for some suicide prevention efforts.